Login / Signup

Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy.

Elisa MeucciAnna RadiceFilippo FassioMaria Loredana Chiara IornoDonatella Macchia
Published in: Clinical case reports (2021)
Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • aedes aegypti
  • chronic kidney disease
  • peritoneal dialysis
  • dengue virus
  • early onset
  • mesenchymal stem cells
  • replacement therapy
  • drug induced